SANUWAVE Health, Inc. (SNWV): debt financing — SANUWAVE Health closes $1.9M convertible note financing with 93M warrants

On December 30, 2023, the Company issued Notes to the Purchasers in an aggregate principal amount of $1.9 million. Pursuant to the Notes, the Company promised to pay each Purchaser, its designee or registered assigns (the "Holder") in cash and/or in shares of common stock, at a conversion price of $0.04 (the "Conversion Price"), the principal amount (subject to reduction pursuant to the terms of the Note, the "Principal") as may be advanced in disbursements (each, a "Disbursement" and together, the "Disbursements," with total principal of outstanding Disbursements equaling Principal), and to pay interest at a rate of fifteen percent (15%) per annum ("Interest") on any outstanding Principal at the applicable Interest rate from the date of the Notes until the Notes are accelerated, converted, redeemed or otherwise.

On December 30, 2023, SANUWAVE Health, Inc. (“SANUWAVE” or the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”), with the purchasers identified on the signature pages thereto (the “Purchasers”) for the sale by the Company in a private placement (the “Private Placement”) of (i) the Company’s future advance convertible promissory notes in an aggregate principal amount of approximately $1.9 million

In connection with the Purchase Agreement, the Company entered into a registration rights agreement with the Purchasers on December 30, 2023 (the “Registration Rights Agreement”),